CheckCell‐2 (NCT05566223), a therapeutic approach based on the CRISPR/Cas9‐encoded CISH gene, was also applied in a clinical trial in patients with metastatic NSCLC.CD70, which has limited expression in normal tissues and is expressed in a wide range of solid tumors and hematological tumors, is able to efficiently modulate T cells and promote immunosuppression in the tumor microenvironment, and it could be used as a target for immunotherapy.402. The gene discussed is CISH; the disease is neoplasm.